1Granerod J,Ambrose HE,Davies NW,et al.Causes of encephali-tis and differences in their clinical presentations in England:amulticenter,population-based prospective study[].The Lancet Infectious Diseases.2010
2Tüzün E,Dalmau J.Limbic encephalitis and variants:classifica-tion,diagnosis and treatment[].Neurologist.2007
1Dingledine R, Borges K, Bowie D, et al. The glutamate receptor ion channels. Pharmacological Reviews, 1999, 51(1): 7-61.
2Yamakura T, Shimoji K. Subunit- and site-specific pharmacology of the NMDA receptor channel. Progress in Neurobiology, 1999, 59(3): 279-298.
3Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacology. Current Opinion in Pharmacology, 2007, 7(1): 39-47.
4Yao Y, Mayer M L. Characterization of a soluble ligand binding domain of the NMDA receptor regulatory subunit NR3A. The Journal of Neuroscience, 2006, 26(17): 4559- 4566.
5Matsuda K, Kamiya Y, Matsuda S, et al. Cloning and characterization of a novel NMDA receptor subunit NR3B: a dominant subunit that reduces calcium permeability. Brain research. Molecular Brain Research, 2002, 100(1-2): 43-52.
6Williams K. lfenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Molecular Pharmacology, 1993, 44(4): 851-859.
7Paoletti P, Ascher P, Neyton J. High-affinity zinc inhibition of NMDA NR1-NR2A receptors. The Journal of Neuroscience, 1997, 17(15): 5711-5725.
8Feng B, Morley R M, Jane D E, et al. The effect of competitive antagonist chain length on NMDA receptor subunit selectivity. Neuropharmacology, 2005, 48(3): 354-359.
9Liu L, Wong T P, Pozza M F, et al. Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science, 2004, 304(5673): 1021-1024.
10Neyton J, Paoletti E Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach. The Journal of Neuroscience, 2006, 26(5): 1331-1333.
4Granerod J,Ambrose HE,Davies NW,et al.Causes of encephalitis and differences in their clinical presentations in England:a multicenter,population-based prospective study[J].Lancet Infect Dis,2010,10(12):835-844.
5Dalmau J,Lancaster E,Martinez-Hernandez E,et al.Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis[J].Lancet Neurol,2011,10(1):63-74.
6Lizuka T,Sakai F.Anti-NMDA receptor encephalitis in Japan:longterm outcome without tumor removal[J].Neurology,2008,70(7):504-511.
7Dalmau J,Gleichman AJ.Anti-NMDA-receptor encephalitis:case series and analysis of the effects of antibodies[J].Lancet Neurol,2008,7(12):1091-1098.
8Ishiura H,Matsuda S.Response of anti-NMDA receptor encephalitis without tumor to immunotherapy including rituximab[J].Neurology,2008,71(23):1921-1923.
9Poloni C,Korff CM,Ricotti V,et al.Severe childhood encephalopathy with dyskinesia and prolonged cognitive disturbances:evidence for anti-N-methyl-D-aspartate receptor encephalitis[J].Dev Med Child Neurol,2010,52:78-82.
